Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Report: Sanofi may make $18.7B bid for Genzyme

July 29, 2010 6:36 am | by Mass High Tech: The Journal of New England Technology | News | Comments

French drug maker Sanofi-Aventis plans to make a formal bid to buy Genzyme Corp., for as much as $18.7 billion, Reuters news agency is reporting, quoting unnamed sources.

Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia

July 29, 2010 6:35 am | by Bio-Medicine.Org | News | Comments

NEW YORK , July 29 /- Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia.  The trial met its primary endpoint...

TOPICS:

Shionogi Inc. Announces FDA Approval of CUVPOSAâ„¢ for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions

July 29, 2010 6:35 am | by Bio-Medicine.Org | News | Comments

FLORHAM PARK, N.J. , July 29 /- Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. Food and Drug Administration approval of CUVPOSA™ (glycopyrrolate), the first liquid treatment for patients ages 3-16 who suffer from chronic severe...

TOPICS:
Advertisement

Vertical Lift Stage Offers 2 nm Resolution

July 29, 2010 6:17 am | Product Releases | Comments

Aerotech’s ANT130-5-V is a linear-motor-driven wedge-style vertical lift stage that provides the exceptional resolution, accuracy, and in-position stability required in nanopositioning applications, all while offering travel up to 5 mm.

Marina Biotech, Inc. Announces Upcoming Investor Conference Presentations

July 29, 2010 5:45 am | by The Associated Press | News | Comments

Marina Biotech, Inc. (NASDAQ: MRNAD), formerly known as MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced that J. Michael French, Marina's President and Chief Executive Officer, will provide an overview of the Company and its progress in key...

Vitamin D deficiency linked to arterial stiffness in black teens

July 29, 2010 4:41 am | by EurekAlert | News | Comments

(The Endocrine Society) Vitamin D deficiency is associated with arterial stiffness, a risk factor for heart disease and stroke, in black teens according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism. Black teens...

TOPICS:

ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24

July 29, 2010 4:37 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO , July 29 /- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced that six of six patients (100%) in the ANA598 200 mg twice daily (bid) arm who were randomized to stop all treatment at Week 24 in an ongoing Phase II trial maintained undetectable levels of virus 12 weeks...

TOPICS:

Free For All® Inc., MMM and PMC Assist Members with Pharmacy Discount

July 29, 2010 4:37 am | by Bio-Medicine.Org | News | Comments

MARLTON, N.J. , July 29 /- Free For All® Inc., MMM Healthcare, Inc. (MMM) and PMC Medicare Choice, Inc. today announced a plan to offer MMM/PMC members access to medications, lab testing and medical imaging at substantial rate reductions with the use of RxCut®Plus cards. The...

TOPICS:
Advertisement

Winner Medical Launches Its First Online PurCotton(R) Store in China on Taobao.com

July 29, 2010 4:36 am | by Bio-Medicine.Org | News | Comments

SHENZHEN, China , July 29 /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: WWIN ) ("Winner," or "the Company"), a leading manufacturer of medical dressings, medical disposables and non-woven PurCotton(R) materials for the medical and consumer products industries, announced today...

TOPICS:

IRIDEX Granted U.S. Patent for Adjustable Laser Probe for Eye Surgery

July 29, 2010 4:36 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif. , July 29 /- IRIDEX Corporation (Nasdaq: IRIX ) today announced the receipt of an Issue Notification from the U.S. Patent and Trademark Office for U.S. Patent No. 7,766,904, "Adjustable Laser Probe For Use In Vitreoretinal Surgery." This patent applies to a number of...

TOPICS:

Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010

July 29, 2010 4:36 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO , July 29 /- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity, will announce its second quarter ended June 30, 2010 financial results on Thursday, August 5, 2010 after the markets close. The announcement will be...

TOPICS:

AdvanDx Receives FDA 510(k) Clearance for 90 Minutes Protocol for Yeast Traffic Light® PNA FISH®

July 29, 2010 4:36 am | by Bio-Medicine.Org | News | Comments

WOBURN, Mass.and VEDBAEK, Denmark , July 29 /- AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its Yeast Traffic Light® PNA FISH® test.  The faster protocol reduces the PNA FISH turn-around time from the original 2.5...

TOPICS:

BD Announces Promotion of President Vince Forlenza; Gains Additional Title of Chief Operating Officer

July 29, 2010 4:33 am | by Becton, Dickinson and Company | News | Comments

(July 28, 2010) -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the promotion of Vincent A. Forlenza, President, who assumes the title of Chief Operating Officer in addition to his current title. Mr. Forlenza

TOPICS:

Integra LifeSciences 2Q profit rises 35 percent

July 29, 2010 3:45 am | by The Associated Press | News | Comments

Medical device maker Integra LifeSciences Holdings Corp. said Thursday its profit grew 35 percent in the second quarter as product sales increased, and the company took fewer charges.The company said its profit rose to $15.2 million, or 50 cents per share, from $11.2 million, or 38 cents per...

New lab test could identify imatinib resistance

July 28, 2010 10:35 pm | by EurekAlert | News | Comments

(American Association for Cancer Research) Scientists in Japan may have developed a way to accurately predict those patients who will resist treatment with imatinib, which is the standard of care for chronic myeloid leukemia.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading